
Ypsomed sells its diabetes business and grows by over 35%
Ad hoc announcement pursuant to Art. 53 LR

Ypsomed sells its diabetes care business to TecMed AG to become a pure play self-injection specialist
Ad hoc announcement pursuant to Art. 53 LR

Ypsomed significantly increases sales and decides to initiate the sale of Diabetes Care
Ad hoc announcement pursuant to Art. 53 LR

Ypsomed significantly increases its operating profit and plans to have two independent business areas
Ad hoc announcement pursuant to Art. 53 LR

Ypsomed sells its pen needle and BGM business to MTD and invests in the expansion of its Solothurn site
Ad hoc announcement pursuant to Art. 53 LR